AMG National Trust Bank Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AMG National Trust Bank increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220 shares of the biopharmaceutical company’s stock after purchasing an additional 28 shares during the quarter. AMG National Trust Bank’s holdings in Regeneron Pharmaceuticals were worth $231,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Swiss National Bank increased its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Regeneron Pharmaceuticals by 16.7% in the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock valued at $9,587,000 after acquiring an additional 1,306 shares during the period. Claro Advisors LLC grew its position in Regeneron Pharmaceuticals by 110.6% during the 3rd quarter. Claro Advisors LLC now owns 478 shares of the biopharmaceutical company’s stock worth $502,000 after purchasing an additional 251 shares during the last quarter. Concord Asset Management LLC VA grew its holdings in shares of Regeneron Pharmaceuticals by 16.7% during the third quarter. Concord Asset Management LLC VA now owns 1,064 shares of the biopharmaceutical company’s stock worth $1,119,000 after buying an additional 152 shares during the last quarter. Finally, Atlanta Consulting Group Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $534,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $744.60 on Wednesday. The company has a 50 day simple moving average of $969.72 and a 200-day simple moving average of $1,032.16. Regeneron Pharmaceuticals, Inc. has a 52-week low of $736.19 and a 52-week high of $1,211.20. The firm has a market capitalization of $81.82 billion, a price-to-earnings ratio of 18.43, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Finally, TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.